Document is current

Article History

Received: 31 October 2021

Accepted: 21 March 2022

First Online: 31 March 2022

Declarations

:

: The Medical Ethics Review Committee of Seirei Hamamatsu General Hospital approval no. 3310 and the Faculty of Pharmacy, Osaka Medical Pharmaceutical University, approved this study, approval no. 0088. All procedures were performed in accordance with the ethical standards of the Seirei Hamamatsu General Hospital and Osaka Medical Pharmaceutical University of Medicine Institutional Medical Ethics Review Committee and the 1964 Declaration of Helsinki and its later amendments. No prospective studies with human participants or animals were performed by any of the authors for this article.This study retrospectively analyzed 208 cancer patients newly prescribed laxatives for OIC or OIC prevention at Seirei Hamamatsu General Hospital between November 2016 and June 2021. All study protocols were approved by the Medical Ethics Review Committee at Seirei Hamamatsu General Hospital (approval no. 3310) and the Faculty of Pharmacy at Osaka Medical Pharmaceutical University (approval no. 0088).

: Given the retrospective nature of this work, the need to obtain informed consent was waived for the individual participants included in the study, in accordance with the standards of the Seirei Hamamatsu General Hospital and Osaka Medical Pharmaceutical University of Medicine Institutional Medical Ethics Review Committee.

: All authors give their consent for this manuscript to be published in <i>Supportive Care in Cancer.</i>

: The authors declare no competing interests.